The FDA approved the first use of Trace-Ability’s Tracer-QC at Massachusetts General Hospital for testing of an imaging agent used in positron emission tomography (PET)-N-13 ammonia for injection, according to a release.
Tracer-QC automates the conventional PET tracer release testing process.
"Our goal is to help the industry transition to a more streamlined PET drug production and quality control workflow," says Daniel Yokell, associate director for dadiopharmacy and regulatory affairs at the Gordon Center for Medical Imaging at Massachusetts General Hospital. "In turn we can hopefully expand patient access to these critical diagnostic procedures outside of large academic medical centers."
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.